Picks up Gallus Pharma, whose plants are in St. Louis and Princeton, NJ
As Big Pharma gets bigger through acquisitions (like the recently announced Roche-InterMune deal), contract development and manufacturing orgnizations (CDMOs) are keeping pace. The latest merger is DPx Holdings’ purchase of Gallus Pharmaceuticals, headquartered in St. Louis. Gallus will be folded into the Patheon unit of DPx, which itself came together through the merger of Patheon and parts of DSM Fine Chemicals this spring.
Last year, Gallus had acquired Laureate Pharmaceuticals (which brought the Princeton facility). DSM brought a recent acquisition, Banner PharmaCaps, into the DPx unit. Private equity firms are driving some of this merging; Gallus is owned by Ridegmont Equity Partners; DPx is jointly owned by DSM, the Dutch chemicals and industrial products giant, and JLL Partners, with JLL as majority owner.
AT the time of the DPx formation, employment measured 8,000, in 24 locations worldwide. Gallus brings an additional 370 employees.
Protecting Temperature-Sensitive Pharmaceuticals, Without Unnecessary Plastic Waste
March 24th 2025Advances in the life sciences are driving a significant increase in the number of temperature-sensitive pharmaceuticals. The packaging industry is meeting the moment with advances of its own, including high-performance, environmentally-friendly materials that allow life science companies meet stringent thermal requirements and ambitious CO2e reduction goals. In this episode, TemperPack’s CEO Peter Wells shares insights from working with life sciences to move to certified biobased, home compostable, and curbside recyclable shipping solutions.